1 drug(s) with this reaction
3,272 total reports
Device Occlusion has been reported as an adverse reaction across 1 drug(s) manufactured by Amgen Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 3,272 adverse event reports mention device occlusion in connection with Amgen Inc products.
This page provides a breakdown of which Amgen Inc drugs are most commonly associated with device occlusion, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Amgen Inc drugs have device occlusion listed in their FDA adverse event reports, sorted by report count:
In addition to device occlusion, the following adverse reactions have been reported across Amgen Inc's drug portfolio:
1 drug(s) manufactured by Amgen Inc have device occlusion listed in their FDA adverse event reports: PEGFILGRASTIM.
There are a combined 3,272 reports of device occlusion across 1 Amgen Inc drug(s) in the FDA adverse event database.